HeartSciences Secures Korean Patent for Innovative Heart Disease Detection Device
HeartSciences is focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Its lead product candidate is the MyoVista® for early heart disease detection.
- The company expects to resubmit its De Novo classification request to the FDA in the current fiscal year.
- TheMyoVista® is designed to detect LV Diastolic Dysfunction, an early biomarker for heart disease. It is a Class II non-significant risk device.
- HeartSciences has been granted nine US patents and 30 international patents to date, covering key markets including China, Brazil, Canada, India, South Korea, Mexico, Germany, France, UK, Italy and the Netherlands.
HeartSciences expects its intellectual property portfolio to be a source of major competitive advantage as it moves toward commercialization.